Diabetes mellitus and latent tuberculosis infection: baseline analysis of a large UK cohort.

We conducted a cross-sectional analysis of baseline data from a UK cohort study which enrolled participants at risk of latent tuberculosis infection (LTBI, defined as a positive result for either of the two interferon gamma release assays). Binomial regression with a log link was used to estimate crude and adjusted prevalence ratios (PRs) and 95% CIs for the relationship between diabetes mellitus (DM) and LTBI. Adjusted for age, sex, ethnicity, body mass index and the presence of other immunocompromising conditions, DM was associated with a 15% higher prevalence of LTBI (adjusted PR=1.15, 95% CI 1.02 to 1.30, p=0.025). TRIAL REGISTRATION NUMBER: PREDICT is registered on clinicaltrials.gov (NCT01162265).

Informations de copyright

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Déclaration de conflit d'intérêts

Competing interests: CJ has undertaken paid consultancy work for Otsuka Pharmaceutical unrelated to the content of this paper. AL has several issued patents underpinning immunodiagnostics for tuberculosis. The ESAT-6/CFP-10 interferon-gamma ELISpot was commercialised by an Oxford University spin-out company (Oxford Immunotec, Abingdon, UK) from which Oxford University and AL have royalty entitlements.